Literature DB >> 22840742

Contralateral occlusion is not a clinically important reason for choosing carotid artery stenting for patients with significant carotid artery stenosis.

Luke P Brewster1, Robert Beaulieu, Karthik Kasirajan, Matthew A Corriere, Joseph J Ricotta, Siddharth Patel, Thomas F Dodson.   

Abstract

OBJECTIVE: Contralateral carotid artery occlusion by itself carries an increased risk of stroke. Carotid endarterectomy (CEA) in the presence of contralateral carotid artery occlusion has high reported rates of perioperative morbidity and mortality. Our objective was to determine if there is a clinical benefit to patients who receive carotid artery stenting (CAS) compared to CEA in the presence of contralateral carotid artery occlusion.
METHODS: We conducted a retrospective medical chart review over a 4.5-year institutional experience of persons with contralateral carotid artery occlusion and ipsilateral carotid artery stenosis who underwent CAS or CEA. The main outcome measures were 30-day cardiac, stroke, and mortality rate, and midterm mortality.
RESULTS: Of a total of 713 patients treated for carotid artery stenosis during this time period, 57 had contralateral occlusion (~8%). Thirty-nine of these patients were treated with CAS, and 18 with CEA. The most common indications for CAS were prior neck surgery (18), contralateral internal carotid occlusion (nine), and prior neck radiation (seven). The average age was 70 ± 8.5 for CEA and 66.7 ± 9.3 for CAS (P = .20). Both groups were predominantly men (CEA 12 of 18; CAS 28 of 39; P = .76), with similar prevalence of symptomatic lesions (CEA 8 of 18, CAS 20 of 39; P = .77). Two patients died within 30 days in the CAS group (5%). No deaths occurred within 30 days in the CEA group (P = .50); the mortality rate for CAS and CEA combined was 3.5%. No perioperative strokes or myocardial infarction occurred in either group. Two transient ischemic attacks occurred after CAS. At mean follow-up of 29.4 ± 16 months (CEA) and 28 ± 14.4 months (CAS; range, 1.5-48.5 months), seven deaths occurred in the CAS group and one in the CEA group (17.9% vs 5.5%; P = .40). There were two reinterventions in the CAS group for in-stent restenosis and there were no reoperations in the CEA group.
CONCLUSIONS: Although CEA and CAS can both be performed with good perioperative results and acceptable midterm mortality, the observed outcomes do not support use of contralateral carotid artery occlusion as a selection criterion for CAS over CEA in the absence of other indications.
Copyright © 2012 Society for Vascular Surgery. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22840742     DOI: 10.1016/j.jvs.2012.04.033

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  4 in total

1.  Perioperative and follow-up results in carotid artery stenting with contralateral carotid occlusion.

Authors:  Ahmet Peker; Mine Hayriye Sorgun; Canan Togay Isikay; Ethem Murat Arsava; Mehmet Akif Topcuoglu; Anil Arat
Journal:  Jpn J Radiol       Date:  2016-05-26       Impact factor: 2.374

Review 2.  Systematic Review and Meta-Analysis of Carotid Artery Stenting Versus Endarterectomy for Carotid Stenosis: A Chronological and Worldwide Study.

Authors:  Lei Zhang; Zhiqing Zhao; Yaoming Ouyang; Junmin Bao; Qingsheng Lu; Rui Feng; Jian Zhou; Zaiping Jing
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

3.  Selecting an appropriate surgical treatment instead of carotid artery stenting alone according to the patient's risk factors contributes to reduced perioperative complications in patients with internal carotid stenosis: a single institutional retrospective analysis.

Authors:  Kimitoshi Sato; Sachio Suzuki; Masaru Yamada; Hidehiro Oka; Akira Kurata; Hirotsugu Okamoto; Kiyotaka Fujii; Toshihiro Kumabe
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-01-23       Impact factor: 1.742

4.  Contralateral occlusion increases the risk of neurological complications associated with carotid endarterectomy.

Authors:  Laura Capoccia; Enrico Sbarigia; Anna Rita Rizzo; Chiara Pranteda; Danilo Menna; Pasqualino Sirignano; Wassim Mansour; Andrea Esposito; Francesco Speziale
Journal:  Int J Vasc Med       Date:  2015-01-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.